In a follow-up study, MMP 2/9 were found to be decreased in sorafenib-treated RCC cells characterized by inhibited cell migration and invasion while the artificial overexpression of CREB1 reversed sorafenib-induced effects in these cells21. Here, CREB1 is linked to renal cell carcinoma.